The Urology Laser Machine industry trends over the past 18 months underscore a decisive shift toward outpatient, stone-focused care and AI-guided ablation. In March 2024, Boston Scientific paid $1.7 billion for Axonics, instantly expanding its urology laser ecosystem to include rechargeable sacral neuromodulators paired with thulium fiber units for stone and BPH cases. Olympus countered in July by launching the *Soltive™ Premium with 50 W super-pulse thulium, the first system cleared under FDA’s tightened 510(k) cybersecurity addendum that now demands evidence-based risk files. Meanwhile, Lumenis secured a five-year sole-source deal with HCA Healthcare (1,200 beds across eight U.S. ASCs) to install its Moses 2.0 holmium platform, accelerating migration of complex stone surgeries to ambulatory settings—a patient preference echoed by CMS’s 2025 ASC-pay bump for laser lithotripsy (APC 5375). Venture funding has mirrored this decentralization: Zenflow closed a $32 m Series C for its disposable laser-compatible ureteral stent, and FEMSelect raised €18 m to bring a mobile, battery-powered thulium fiber unit to EU imaging centers. Collectively, these moves forecast a 14 % CAGR in compact, high-repetition-rate systems through 2027.